Hepatitis Drug Market Analysis, Size, Share & Growth Forecast 2026–2034

Pangenotypic DAA Cure of HCV With Mavyret and Epclusa Achieving 95 to 99 Percent SVR12 in 8 to 12 Weeks Across All Genotypes Without Interferon Has Transformed HCV From an Incurable Chronic Liver Disease to a Curable Infection That Primary Care Can Manage.AbbVie's Mavyret generic pan-genotypic regimen produced under licence in India, Egypt, and China at under USD 50 per course has enabled treatment of over 90% of HCV genotypes without prior genotyping in resource-limited settings, accelerating WHO's 2030 HCV elimination targets across high-prevalence countries. National elimination programmes in Egypt, Georgia, Mongolia, and Iceland have demonstrated that population-scale HCV screening followed by DAA treatment can reduce chronic HCV prevalence by 80-plus percent within 5 years when treatment access is universal and unlinked to specialist referral requirements. The remaining HCV treatment gap is concentrated in people who inject drugs, incarcerated populations, and migrants who are systematically excluded from conventional healthcare settings, and harm reduction organisations are advancing decentralised community pharmacy and prison-based treatment models that extend DAA access beyond traditional hepatology clinic pathways.

HBV cccDNA Intrahepatic Stable Reservoir That NUC Therapy Suppresses But Cannot Eliminate Remains the Fundamental Barrier to HBV Functional Cure That siRNA, Capsid Assembly Modulators, and Immune Restoration Approaches Are Targeting in Combination.Roche's RO7062931 GalNAc-siRNA targeting hepatitis B surface antigen and core antigen demonstrated 90-plus percent HBsAg reduction in Phase 2, and Vir Biotechnology's VIR-2218 achieved similar HBsAg suppression, establishing RNA interference as the most potent HBsAg-lowering approach yet tested. Combining HBsAg suppression with toll-like receptor 7 agonist immune stimulation from Roche's RO7020531 or with capsid assembly modulator from Janssen is being tested in multi-mechanism Phase 2 trials that aim to achieve HBsAg loss rates above 30% that single-mechanism approaches cannot achieve. The INSIGHT trial combining siRNA with nucleo(s/t)ide analogue and TLR7 agonist in approximately 800 patients is the largest functional-cure combination trial in HBV and will generate the first evidence that combined mechanism approaches can achieve the functional cure benchmark of HBsAg loss with HBV surface antibody seroconversion.

Bulevirtide NTCP Entry Inhibitor for HBV-HDV Coinfection Providing the First Approved Treatment for the Most Severe Viral Hepatitis Form Has Addressed the Unmet Need in HBV-HDV Coinfection That the Existing HBV NUC Therapy Could Not Reduce HDV Replication.Gilead Sciences's tenofovir alafenamide TAF-based regimens demonstrate equivalent HBV DNA suppression to TDF at 96-plus weeks with 50-70% lower tenofovir plasma concentrations that produce significantly less renal tubular toxicity and bone mineral density loss in patients receiving long-term treatment. The switch from TDF to TAF in chronic HBV patients with renal impairment or baseline osteoporosis is supported by switching studies showing rapid improvement in renal biomarkers within 48 weeks, and AASLD and EASL guidelines recommend TAF as the preferred nucleo(s/t)ide analogue for newly initiated patients and for patients with evidence of TDF-related renal or bone adverse effects. TAF patent protection extends the commercial lifecycle of Gilead Sciences's HBV franchise beyond TDF's generic entry, and the TAF backbone in combination with future surface antigen-reducing and immune-stimulating agents positions Gilead at the centre of functional-cure combination strategy.

For related market intelligence, see the Pharmaceutical Market.